4-amino-N-[2-(diethylamino)ethyl]benzamide

• ChemBase编号: 907
• 分子式: C13H21N3O
• 平均质量: 235.32534
• 单一同位素质量: 235.16846231
• SMILES: O=C(NCCN(CC)CC)c1ccc(N)cc1
• Canonical SMILES: CCN(CCNC(=O)c1ccc(cc1)N)CC
• InChI: InChI=1S/C13H21N3O/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3,(H,15,17)
• InChIKey: REQCZEXYDRLIBE-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 4-amino-N-[2-(diethylamino)ethyl]benzamide
• IUPAC传统名: procainamide
• 商标名: Biocoryl; Novocainamid; Novocainamide; Novocaine Amide; Novocamid; Procainamide Hcl; Procaine Amide; Procamide; Procan; Procan Sr; Procanbid; Procapan; Promine; Pronestyl; Pronestyl-Sr
• 别名: Procainamide

登记号

• CAS号: 51-06-9
• PubChem SID: 46507313; 160964370
• PubChem CID: 4913

理论计算性质

JChem

• Acid pKa: 15.7515745
• 质子受体: 3
• 质子供体: 2
• LogD (pH = 5.5): -2.27341
• LogD (pH = 7.4): -0.69723266
• Log P: 0.9508967
• 摩尔折射率: 72.2498 cm^3
• 极化性: 26.875093 Å^3
• 极化表面积: 58.36 Å^2
• 可自由旋转的化学键: 6
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 1.42
• LOG S: -1.89
• 溶解度: 3.02e+00 g/l

分子性质

理化性质

• 溶解度: 5050 mg/L
• 疏水性(logP): 1.3

详细说明

DrugBank - DB01035

• Drug Groups: approved
• Description: A derivative of procaine with less CNS action. [PubChem]
• Indication: For the treatment of life-threatening ventricular arrhythmias.
• Pharmacology: Procainamide is an agent indicated for production of local or regional anesthesia and in the treatment of ventricular tachycardia occurring during cardiac manipulation, such as surgery or catheterization, or which may occur during acute myocardial infarction, digitalis toxicity, or other cardiac diseases. The mode of action of the antiarrhythmic effect of Procainamide appears to be similar to that of procaine and quinidine. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. The sinoatrial node is, however, unaffected.
• Toxicity: LD₅₀=95 mg/kg (rat, IV); LD₅₀=312 mg/kg (mouse, oral); LD₅₀=103 mg/kg (mouse, IV); LD₅₀=250 mg/kg (rabbit, IV)
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic
• Absorption: 75 to 95%
• Half Life: ~2.5-4.5 hours
• Protein Binding: 15 to 20%
• Elimination: Trace amounts may be excreted in the urine as free and conjugated p-aminobenzoic acid, 30 to 60 percent as unchanged PA, and 6 to 52 percent as the NAPA derivative.
• Distribution: * 2 L/kg
• External Links: Wikipedia; RxList; Drugs.com